Format

Send to

Choose Destination
Br J Dermatol. 2018 May;178(5):1083-1101. doi: 10.1111/bjd.16156. Epub 2018 Mar 25.

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).

Author information

1
University Medical Center Utrecht, Utrecht, the Netherlands.
2
University of Lübeck, Lübeck, Germany.
3
St. John's Institute of Dermatology, London, U.K.
4
Dermatologikum and TFS Research Institute, Hamburg, Germany.
5
Sheffield Dermatology Research, The University of Sheffield, Sheffield, U.K.
6
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, U.S.A.
7
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, U.S.A.
8
Sanofi, Chilly-Mazarin, France.
9
Sanofi, Cambridge, MA, U.S.A.
10
Sanofi, Bridgewater, NJ, U.S.A.

Abstract

BACKGROUND:

Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side-effects limit its use. Dupilumab, a fully human anti-interleukin 4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of Type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately-controlled moderate-to-severe atopic dermatitis in adults.

OBJECTIVES:

To evaluate efficacy and safety of dupilumab with concomitant topical corticosteroids (TCS) in adults with atopic dermatitis with inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable.

METHODS:

In this 16-week, double-blind, randomized, placebo-controlled, phase III trial, patients were randomized 1 : 1 : 1 to subcutaneous dupilumab 300 mg weekly (qw) or every 2 weeks (q2w) or placebo. All received concomitant medium-potency TCS from Week -2 through Week 16; dosage could be tapered if lesions cleared, or stopped for adverse reactions to TCS.

RESULTS:

In total, 390 patients were screened, 325 were randomized, and 318 completed the trial. Treatment groups had similar baseline characteristics. Significantly more patients in the dupilumab qw + TCS and q2w + TCS groups achieved ≥ 75% improvement from baseline in the Eczema Area and Severity Index at Week 16 vs. the placebo + TCS group (primary end point) (59·1% and 62·6% vs. 29·6%, respectively; P < 0·001 vs. placebo + TCS, both doses). Other clinical outcomes and atopic dermatitis symptoms were significantly improved in the dupilumab qw + TCS and q2w + TCS groups, including pruritus, pain, sleep disturbance, symptoms of anxiety and depression, and quality of life (QoL). Treatment groups had similar overall rates of adverse events (qw + TCS, q2w + TCS and placebo + TCS groups: 69·1%, 72·0% and 69·4%, respectively) and serious adverse events (1·8%, 1·9% and 1·9%, respectively). Conjunctivitis was more frequent with dupilumab + TCS; skin infections were more frequent with placebo + TCS.

CONCLUSIONS:

Dupilumab + TCS significantly improved signs and symptoms of atopic dermatitis and QoL in adults with a history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified.

PMID:
29193016
DOI:
10.1111/bjd.16156
Free full text

Supplemental Content

Full text links

Icon for Wiley Icon for White Rose Research Online
Loading ...
Support Center